Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Pembrolizumab Improves 5-year OS in Advanced NSCLC

Key clinical point: Pembrolizumab increased 5-year overall survival for patients with advanced non–small cell lung cancer.

Major finding: The 5-year overall survival rate was 23.2% in treatment-naive patients and 15.5% in previously treated patients who received pembrolizumab in this study.

Study details: Phase 1b trial including 550 patients with advanced NSCLC.

Disclosures: The lead author disclosed relationships with AstraZeneca, Bristol-Myers Squibb, Dracen, Dynavax, Genentech, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, and Novartis. The trial was sponsored by Merck Sharp & Dohme Corp.


Garon E et al. ASCO 2019, Abstract LBA9015. J Clin Oncol. 2019 June 2. doi: 10.1200/JCO.19.00934.